Posted by Michael Wonder on 21 Feb 2023
First gene therapy for haemophilia B, CSL's Hemgenix, approved by the European Commission
20 February 2023 - Hemgenix underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives.
CSL today announced that the European Commission has granted conditional marketing authorisation for Hemgenix (etranacogene dezaparvovec), the first and only one time gene therapy for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adults without a history of factor IX inhibitors.
